DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL)

Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukemia

Intervention: Clofarabine (Drug); Idarubicin (Drug); Cytarabine (Drug); Vincristine (Drug); Rituximab (Drug); Dexamethasone (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: M.D. Anderson Cancer Center

Official(s) and/or principal investigator(s):
Elias Jabbour, MD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center

Overall contact:
Elias Jabbour, MD, Phone: 713-792-4764

Summary

The goal of this clinical research study is to learn if the combination of clofarabine, idarubicin, cytarabine, vincristine, and dexamethasone, with or without rituximab, can help to control mixed phenotype acute leukemia. The safety of this combination will also be studied.

Clinical Details

Official title: A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Response Rate

Detailed description: Study Drug Administration: The study drugs will be given in what are called cycles. Each cycle is 28 days. Induction: The first cycle of study drugs is called Induction. If the doctor thinks it is needed, you will have up to 2 Induction cycles. During Induction cycles, you will receive:

- Clofarabine by vein over about 60 minutes on Days 1-4. If the doctor thinks it is in

your best interest, you will only receive it on Days 1-3.

- Idarubicin by vein over about 30-60 minutes on Days 1-3, about 1-2 hours after you

receive clofarabine. If the doctor thinks it is in your best interest, you will only receive it on Days 1 and 2.

- Cytarabine by vein over about 2 hours on Days 1-4, about 3-6 hours after you receive

clofarabine.

- Vincristine by vein over about 15-30 minutes on Days 1, 8, and 15.

- Dexamethasone by vein over about 10-30 minutes on Days 1-4 and 15-18. If you have a

certain type of leukemia and the doctor thinks it is in your best interest, you will also receive rituximab by vein over about 4-6 hours on Days 1 and 11. The study staff will tell you if you will receive rituximab. If the doctor thinks it is in your best interest, your dose will be reduced after Induction. Consolidation: If the disease responds to the study drugs during Induction, you may receive up to 6 more cycles of study drugs. This is called Consolidation. During Consolidation cycles, you will receive:

- Clofarabine by vein over about 60 minutes on Days 1-3. If the doctor thinks it is in

your best interest, you will only receive it on Days 1-2.

- Idarubicin by vein over about 30-60 minutes on Days 1-2, about 1-2 hours after you

receive clofarabine.

- Cytarabine by vein over about 2 hours on Days 1-3, about 3-6 hours after you receive

clofarabine. If the doctor thinks it is in your best interest, you will only receive it on Days 1 and 2.

- Vincristine by vein over about 15-30 minutes on Days 1, 8, and 15.

- Dexamethasone by vein over about 10-30 minutes on Days 1-4 and 15-18.

- If you have a certain type of leukemia and the doctor thinks it is in your best

interest, you will also receive rituximab in Consolidation Cycles 1-3, by vein over about 4-6 hours on Days 1 and 11. The study staff will tell you if you will receive rituximab. Study Visits: Before each cycle, you will have a physical exam. Every 3-7 days, blood (about 2-3 teaspoons) will be drawn for routine tests. At the end of every cycle (+/- 7 days), you will have a bone marrow aspirate/biopsy collected to check the status of the disease and for cytogenetic testing. If the disease appears to get better, you will have these study visits less often. Blood will be drawn every 7-14 days, and you will only have a bone marrow aspirate/biopsy when the study doctor thinks it is needed. Length of Study: You may continue receiving the study drugs for 1-2 induction cycles and then up to 6 consolidation cycles. You will no longer be able to receive the study drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. Your participation on the study will be over after you have completed the end-of-study visit, unless you will have maintenance treatment as discussed by you and the study doctor. End-of-Study Visit: You will have an end-of-study visit about 30 days after you stop receiving the study drugs. At this visit, the following tests and procedures will be performed:

- You will have a physical exam.

- Blood (about 2-3 teaspoons) will be drawn for routine tests.

- If the study doctor thinks it is needed, you will have a bone marrow aspirate and/or

biopsy.

- If you can become pregnant, you will have a urine pregnancy test.

This is an investigational study. Clofarabine is FDA approved and commercially available to treat acute lymphoblastic leukemia (ALL) in children. Idarubicin and cytarabine are FDA approved and commercially available to treat acute myeloid leukemia (AML). Rituximab is FDA approved and commercially available to treat various types of lymphoma and leukemia. The use of these drugs in combination with vincristine and dexamethasone to treat mixed phenotype acute leukemia is investigational. The study doctor can explain how the drugs are designed to work. Up to 60 participants will be enrolled in this study. All will take part at MD Anderson.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Sign an informed consent document 2. Age 18 to 65. 3. Newly diagnosed or relapsed MPAL, which for this protocol, will be defined as

follows: - Bone marrow result interpreted by the reading Pathologist (or tissue biopsy

for cases of extramedullary disease) as: biphenotypic leukemia, bilineal leukemia, undifferentiated leukemia, mixed lineage leukemia, leukemia of ambiguous lineage, T/Myeloid leukemia, B/Myeloid leukemia, or other diagnosis indicating the presence of multiple lineages within the cell population. 4. ECOG Performance Status of /= 40% (by either cardiac echo or MUGA scan). Documentation of recent (

Locations and Contacts

Elias Jabbour, MD, Phone: 713-792-4764

University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
Additional Information

University of Texas MD Anderson Cancer Center Website

Starting date: October 2014
Last updated: March 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017